LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsGlobeNewsWire • 03/21/24
Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer ResearchGlobeNewsWire • 02/27/24
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCIGlobeNewsWire • 02/26/24
First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialGlobeNewsWire • 01/29/24
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsGlobeNewsWire • 11/13/23
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachGlobeNewsWire • 10/09/23
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerGlobeNewsWire • 09/20/23
LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 07/20/23
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing RequirementsGlobeNewsWire • 06/23/23
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE's Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue SarcomasGlobeNewsWire • 06/07/23
LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023GlobeNewsWire • 06/02/23
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology's Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer ImmunotherapyGlobeNewsWire • 05/30/23
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue SarcomaGlobeNewsWire • 04/24/23
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope's Ongoing Phase 1b Clinical Trial in Evaluating Lixte's Lead Anti-Cancer Compound, LB-100, in Small Cell Lung CancerGlobeNewsWire • 04/04/23
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCHGlobeNewsWire • 02/14/23
LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELSGlobeNewsWire • 02/07/23
LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor ConferenceAccesswire • 11/30/22
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUPGlobeNewsWire • 10/13/22
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORSGlobeNewsWire • 06/21/22
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORSGlobeNewsWire • 06/15/22